New Objective PicoChip: The Most Comprehensive LC-MS Platform for Immunopeptidomics

March 1st, 2023 – Littleton, MA (USA) New Objective, Inc., the global leader in innovative solutions for nanoflow and microflow LC-MS, offering the most comprehensive LC-MS platform for protein analysis enables researchers at Regeneron Pharmaceuticals in their development of antibody-based therapies through the use of New Objective’s PicoChip® integrated solution for immunopeptidomic analysis. In a recent webinar hosted by Mike Lee, CEO and Emily Ehrenfeld, Co-Founder and President, New Objective on February 15th, 2023, titled Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues, Robert Salzler and Mayank Srivastava, Regeneron, shared recent work and ongoing studies at Regeneron Pharmaceuticals where they are interrogating the immunopeptidome to find novel targets.

Robert shared the importance of mass spectrometry as a tool in the laboratories at Regeneron, as he together with Mayank and their colleagues look to identify the peptides that are presented on the surface of cells and emphasized mass spectrometry as “the only tool for this”. The New Objective SilicaTip™, the standard powering LC-MS analysis, has been an integral component in the LC-MS workflows at Regeneron and is the heart of the unmatched performance of New Objective solutions in the field of LC-MS. As Robert stated, “our mass specs run all the time and we needed robust emitters”. PicoChip, built on a SilicaTip with a frit (PicoFrit®), packed into a column and packaged into the PicoChip, delivers a packaged solution that is scalable to any application and facilitates reliable, reproducible and rugged analysis for quantitative studies that can be measured “injection-to-injection, chip-to-chip, lab-to-lab and study-to-study”, as highlighted by Emily.

We needed robust emitters – our mass specs run all of the time. Very happy with these (PicoChip) – will be the foundation of our system.” – Robert Salzler, Regeneron

Robert, emphasized their work at Regeneron with immunopeptidomics, stating it broadens the repertoire of their analysis and understanding of the HLA (human leukocyte antigen) peptide, offering effective combination immunotherapies – core to the purpose of Regeneron as a company offering antibody-based therapies (“we are an antibody company”) and critical to patients across the globe with unmet therapeutic need. New Objective and its comprehensive solutions, starting with the SilicaTip and ongoing with the PicoChip and FlowChip™, is facilitating the progression of these developments. Through Robert’s experience with New Objective and PicoChip – “very happy with these – will be the foundation of our system”- PicoChip is delivering results that are reliable, reproducible and rugged, transforming the power of the emitter, the SilicaTip, into meaningful results through the work led by Robert and his colleagues at Regeneron.